

CONFIDENTIAL



**TheraGuide 5-FU™
Analysis Result**

PHYSICIAN
Jane Doe MD
Myriad Genetic, Inc.
320 Wakara Way
Salt Lake City, UT 84108

SPECIMEN
Specimen Type: **Blood**
Draw Date: **Jun 26, 2008**
Accession Date: **Jun 27, 2008**
Report Date: **Jun 30, 2008**

PATIENT
Name: **Doe, John**
Date of Birth:
Patient ID:
Gender: **Male**
Accession #: **00254902-BLD**
Requisition #: **00000000**

Test Results and Interpretation

MODERATE RISK

<u>Genes Analyzed</u>	<u>Results</u>	<u>Interpretation</u>
DPYD	No Variant Detected	No Variant Detected
TYMS	2R/2R	Moderate Risk

DPYD : Dihydropyrimidine dehydrogenase (DPYD) gene analysis identified no mutations. There may be other rare abnormalities at the DPYD locus that are not detected by this analysis.

TYMS : 2R/2R : Thymidylate synthetase (TYMS) gene analysis identified the 2R/2R genotype. In previous studies, patients with this genotype have a 1.4 to 2.5-fold increased risk of 5-FU toxicity compared to the general population [2-5].

Analysis Description: Analysis consists of PCR and DNA sequencing of all 23 coding exons and approximately 690 adjacent intronic base pairs of the DPYD gene. PCR and DNA sequencing analysis is also used to report the number of 28 base pair repeats within the 5' UTR region of the TYMS gene. Rare genetic variants may exist which could lead to a false negative or false positive result.

Additional Information : General information about TheraGuide 5-FU™ can be found at theraguide.com. If you have any questions regarding this report, please do not hesitate to contact Medical Services at 1-800-469-7423.

References:

1. Mol Cancer Ther. 2006; 5(11):2895-2904
2. Clin Cancer Res. 2004; 10(17):5880-5888
3. Clin Cancer Res. 2006; 12(13):3928-3934
4. Pharmacogenomics. 2001; J1:65-70
5. J Clin Oncol. 2008; 26(13):2130-2137

Authorized Signature:

Richard J. Wenstrup, MD Diplomate ABMG Chief Medical Officer	Karla Bowles, Ph.D. Diplomate ABMG Associate Laboratory Director
Benjamin B. Roa, Ph.D. Diplomate ABMG Laboratory Director	Michael G. Rhode, M.D. Diplomate ABP Director, Histopathology Laboratory

The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational in some states. This test was developed and its performance characteristics determined by Myriad Genetics Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.